Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Jordan Translational Medicine Lecture was established following a donation by Professor Craig Jordan (University of Texas MD Anderson Cancer Center) to support an annual lecture in the area of translational research.

upcoming lectures

TBC

 

Past lectures

2022 (October) Prof Dame Carol V. Robinson

Director, Kavli Institute for Nanoscience Discovery, Oxford 

From GroEL Folding to Receptor Signalling Across Native Membranes - The Promises and Pitfalls of Native Mass Spectrometry
2022 (June) Dr Vishva Dixit

Vice-President, Early Discovery Research, Genentech Inc.

Why So Many Ways to Die?
2019 Prof Fiona Watt

Director, King’s Centre for Stem Cells & Regenerative Medicine

Executive Chair, Medical Research Council

Mechanisms Controlling Homeostasis in Mammalian Epidermis
2018 Prof Patrick Cramer

Director, Max Plank Institute of Biophysical Chemistry

How to Switch on Human Genes
2017 Prof Tasuku Honj

Kyoto University, Japan

Cancer Immunotherapy by Blockade of the Lymphocyte Surface Receptor PD-1
2015 Prof Sir Adrian Bird

Wellcome Centre for Cell Biology, UK

Genetic and Epigenetic Roots of an Autism Spectrum Disorder
2014 Prof Rudolf Jaenisch

MIT, USA

iPS Technology, Gene Editing and Disease Research
2013 Prof Craig Jordan, OBE

Georgetown University, USA

Evolution of Endocrine Therapy for Breast Cancer - The Paradox of Estrogen-Induced Apoptosis

 

About Professor Jordan

Prof Craig Jordan

Professor Jordan discovered the biology of a group of medicines now called Selective Estrogen Receptor Modulators (SERMs). These medicines prevent osteoporosis, decrease coronary heart disease and treat and prevent breast cancer. Tamoxifen is the first SERM that has been used as a long-term adjuvant therapy, significantly increasing survival rates for breast cancer patients. The FDA in the United States has approved five SERMs, all of which are connected to Prof Jordan's research. Prof Jordan is a member of the National Academy of Sciences and the National Academy of Medicine, and a Fellow of the Academy of Medical Science. In 2016, he was named one of four individuals who have changed women’s healthcare in the 21st Century and the American Society for Clinical Oncology recognized the impact of his translational research to medical practice. The Jordan Translational Medical Lecture focuses on encouraging further success in translational research.